The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pacira Pharmaceuticals's revenues will increase 37.3% and EPS will remain in the red.
The average estimate for revenue is $16.9 million. On the bottom line, the average EPS estimate is -$0.43.
Last quarter, Pacira Pharmaceuticals booked revenue of $11.6 million. GAAP reported sales were 48% higher than the prior-year quarter's $7.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, EPS came in at -$0.71. GAAP EPS were -$0.71 for Q1 against -$0.47 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 1.7%, much worse than the prior-year quarter. Operating margin was -160.9%, much worse than the prior-year quarter. Net margin was -199.7%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $74.4 million. The average EPS estimate is -$1.70.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 26 members out of 38 rating the stock outperform, and 12 members rating it underperform. Among 10 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), seven give Pacira Pharmaceuticals a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $31.60.
- Add Pacira Pharmaceuticals to My Watchlist.